ClinicalTrials.gg
CompletedNCT01032057SCALOPUpdated Oct 26, 2018

Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

A Phase 2 interventional study of capecitabine and gemcitabine hydrochloride in Pancreatic Cancer, sponsored by Lisette Nixon. Completed at 26 sites in United Kingdom. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2018-10-26.

Sponsored by Lisette Nixon · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies testing capecitabine in Pancreatic Neoplasms — 4 open to participants now, 7 under way, none of them phase 3. Capecitabine · Pancreatic Neoplasms.

Enrollment
13th of 79
114 · median 40
Started
2009
with 7 others
Phase 2
39 of 81
2 open now
Registered
42nd of 81
by date

Among the 81 studies testing capecitabine in Pancreatic Neoplasms, this one is the 13th largest by enrollment of the 79 interventional ones that give a count, is one of 8 that started in 2009, is one of 39 in phase 2, and was the 42nd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

4 of the 81 studies testing capecitabine in Pancreatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies testing capecitabine in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy that uses a 3-dimensional image of the tumor to help focus thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses over a shorter period of time, may kill more tumor cells and have fewer side effects. It is not yet known which regimen of chemotherapy given together with radiation therapy is more effective in treating pancreatic cancer.

PURPOSE: This randomized phase II trial is comparing the side effects of two regimens of gemcitabine and capecitabine given together with radiation therapy and to see how well they work in treating patients with locally advanced pancreatic cancer that cannot be removed by surgery.

Read the detailed description

OBJECTIVES:

  • To evaluate the activity, safety, and feasibility of induction chemotherapy comprising gemcitabine and capecitabine followed by two different schedules of chemoradiotherapy comprising gemcitabine or capecitabine and radiotherapy in patients with locally advanced, nonmetastatic, unresectable pancreatic cancer.
  • To determine which of the two experimental arms gives the highest generic and disease-specific aspects of health-related quality of life (HRQL) following treatment.
  • To determine how HRQL varies during treatment and follow up in both arms.

OUTLINE: This is a multicenter study.

All patients receive a first induction therapy comprising gemcitabine IV on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Following the first induction therapy, patients with a WHO performance status of 0-1 who are responding or have stable disease that can be encompassed within a radically treatable radiotherapy volume are randomized to 1 of 2 treatment arms.

  • Arm I:

    • Second induction therapy (weeks 13-16): Patients receive gemcitabine IV once daily on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21.
    • Chemoradiotherapy (weeks 17-22): Patients receive gemcitabine IV once weekly on day 1 and undergo conformal radiotherapy 5 days a week for 5.5 weeks.
  • Arm II:

    • Second induction therapy (weeks 13-16): Patients receive gemcitabine IV once daily on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21.
    • Chemoradiotherapy (weeks 17-22): Patients receive oral capecitabine twice daily on days 1-5 and undergo conformal radiotherapy 5 days a week for 5.5 weeks.

Patients complete quality-of-life questionnaires QLQ-C30 and PAN26 at baseline and at 17, 23, 26, 39, and 52 weeks.

After completion of study treatment, patients are followed every 3 months.

03

Conditions studied

  • Pancreatic Cancer

Keywords

  • adenocarcinoma of the pancreas
  • stage II pancreatic cancer
  • stage III pancreatic cancer
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • or cytologically confirmed adenocarcinoma of the pancreas

    • Locally advanced, nonmetastatic, inoperable, or operable (but medically unfit for surgery) disease

      • Palliative bypass procedure allowed
      • Common bile duct stenting allowed
  • Primary pancreatic lesion ≤ 7 cm in diameter as measured by CT scan of the thorax and abdomen within 4 weeks prior to registration
  • No recurrent cancer following definitive pancreatic surgery

PATIENT CHARACTERISTICS:

  • (PS) 0-2
  • ≥ 1.5 x 10\^9/L
  • count ≥ 100 x 10\^9/L
  • ≥ 10 g/dL
  • Serum \< 35 μmol/L (50 μmol/L allowed for patients who have had a recent biliary drain and whose bilirubin is descending)
  • /ALT ≤ 2.5 times (ULN)
  • Alkaline phosphatase ≤ 5 times ULN
  • > 50 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective during and for 12 weeks after completion of study therapy
  • No evidence of severe uncontrolled systemic diseases including uncontrolled coronary artery disease
  • No myocardial infarction or stroke within the past 6 months
  • No prior within the past 5 years except for carcinoma in situ of the cervix, adequately treated basal cell skin carcinoma, or any early-stage malignancy
  • No suspected DPD deficiency
  • No renal abnormalities (e.g., adult polycystic kidney disease, hydronephrosis, or ipsilateral single kidney)
  • Must meet the following additional criteria for randomization:

    • WHO PS 0-1
    • Loss of weight no greater than 10% of that at baseline

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • At least 4 weeks since prior and no concurrent sorivudine or analogues
  • No prior radiotherapy to the upper abdomen
  • No concurrent methotrexate
  • No concurrent allopurinol
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Active comparator
    Gemcitabine

    GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po) followed by gemcitabine 300mg/m2 weekly (IV) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)

    Drug: capecitabine · Drug: gemcitabine hydrochloride · Procedure: quality-of-life assessment · Radiation: 3-dimensional conformal radiation therapy

  • Active comparator
    chemoradiotherpay with capecitabine

    GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po), followed by capecitabine 830mg/m2 bd (po, Mon-Fri) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)

    Drug: capecitabine · Drug: gemcitabine hydrochloride · Procedure: quality-of-life assessment · Radiation: 3-dimensional conformal radiation therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival at 39 weeks (from registration) according to RECIST criteria

    Time frame: Assessed 39 weeks from registration

Secondary outcomes

  1. Toxicity according to NCI CTCAE v.3.0

    Time frame: Assessed throughout trial treatment and follow-up

  2. Quality of life as measured by questionnaires QLQ-C30 and PAN26 at baseline and at 17, 23, 26, 39, and 52 weeks

    Time frame: Assessed throughout trial treatment and follow-up

  3. Overall survival at 52 weeks and time from registration to death by any cause

    Time frame: Assessed 52 weeks post registration and during NHS flagging

  4. Objective disease response according to RECIST criteria

    Time frame: 39 weeks post registration

  5. Progression-free survival (time to event) according to RECIST criteria

    Time frame: Assessed during NHS flagging at the end of the trial

  6. Radiotherapy quality assurance (adherence to protocol)

    Time frame: Upon completion of the trial

07

Study locations

26 sites
  • Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust
    Birmingham, England B15 2TH, United Kingdom
  • Bristol Haematology and Oncology Centre
    Bristol, England BS2 8ED, United Kingdom
  • Addenbrooke's Hospital
    Cambridge, England CB2 2QQ, United Kingdom
  • Queen Alexandra Hospital
    Cosham, England PO6 3LY, United Kingdom
  • Castle Hill Hospital
    Cottingham, England HU16 5JQ, United Kingdom
  • Diana Princess of Wales Hospital
    Grimsby, England DN33 2BA, United Kingdom
  • St. Luke's Cancer Centre at Royal Surrey County Hospital
    Guildford, England GU2 7XX, United Kingdom
  • Leeds Cancer Centre at St. James's University Hospital
    Leeds, England LS9 7TF, United Kingdom
  • Leicester Royal Infirmary
    Leicester, England LE1 5WW, United Kingdom
  • Helen Rollason Cancer Care Centre at North Middlesex Hospital
    London, England N18 1QX, United Kingdom
  • Royal Free Hospital
    London, England NW3 2QG, United Kingdom
  • Hammersmith Hospital
    London, England W12 OHS, United Kingdom
  • Northampton General Hospital
    Northampton, England NN1 5BD, United Kingdom
  • Scarborough General Hospital
    Scarborough, England YO12 6QL, United Kingdom
  • Cancer Research Centre at Weston Park Hospital
    Sheffield, England S10 2SJ, United Kingdom
  • Southampton General Hospital
    Southampton, England SO16 6YD, United Kingdom
  • Musgrove Park Hospital
    Taunton, England TA1 5DA, United Kingdom
  • Ninewells Hospital
    Dundee, Scotland DD1 9SY, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, Scotland G12 0YN, United Kingdom
  • Raigmore Hospital
    Inverness, Scotland 1V2 3UJ, United Kingdom
  • Perth Royal Infirmary
    Perth, Scotland PH1 1NX, United Kingdom
  • Ysbyty Gwynedd
    Bangor, Wales LL57 2PW, United Kingdom
  • Velindre Cancer Center at Velindre Hospital
    Cardiff, Wales CF14 2TL, United Kingdom
  • Glan Clwyd Hospital
    Rhyl, Denbighshire, Wales LL 18 5UJ, United Kingdom
  • Wrexham Maelor Hospital
    Wrexham, Wales LL13 7TD, United Kingdom
  • Edith Cavell Hospital
    Peterborough, PE3 9EZ, United Kingdom
08

References and documents

Publications

  • Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):317-26. doi: 10.1016/S1470-2045(13)70021-4. Epub 2013 Mar 6. PubMed 23474363 ↗
  • Fokas E, Spezi E, Patel N, Hurt C, Nixon L, Chu KY, Staffurth J, Abrams R, Mukherjee S. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial. Radiother Oncol. 2016 Aug;120(2):212-6. doi: 10.1016/j.radonc.2016.07.002. Epub 2016 Aug 3. PubMed 27497804 ↗
  • Fokas E, Clifford C, Spezi E, Joseph G, Branagan J, Hurt C, Nixon L, Abrams R, Staffurth J, Mukherjee S. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. Radiother Oncol. 2015 Dec;117(3):432-7. doi: 10.1016/j.radonc.2015.08.026. Epub 2015 Aug 29. PubMed 26328939 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Jan 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2009
First posted
Dec 15, 2009
Start
Jul 2009
Primary completionActual
Jan 2013
CompletionActual
Jun 2013
Last update
Oct 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01032057
Lead sponsor
Lisette Nixon
Responsible party
Lisette Nixon (Dr, Cardiff University) — Sponsor-investigator
First posted
Dec 15, 2009
Start date
Jul 2009
Primary completion
Jan 2013
Completion
Jun 2013
Last update
Oct 26, 2018

Study contacts

Somnath Mukherjee
principal investigator · Northampton General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Gemcitabine

Start the discussion